Symptom Tracker


After the initial testing phase, is finally available this new tool to support patients with Ulcerative Colitis in keeping track of daily changes and improvements with the desease. If you would like to use the tool, register on the homepage and let us know your impressions.

Please check out the tool at:


Any feedback please send  to Isabella Haaf: This email address is being protected from spambots. You need JavaScript enabled to view it.


The tool is supported by an unrestricted grant from the pharmceutical company Shire. 

European Council adoption on patient safety

Patient Safety and Innovation benefiting patients


Earlier this month the European Council adopted two conclusions: one concerning  patient safety  and quality of care, and the second one concerning  innovation for the benefits of patients. Please find a short summary of these conclusions below:


Council conclusions on patient safety and quality of care, including the prevention and control of healthcare associated infections and antimicrobial resistance


The Council recalls that the Annual Growth Survey 2014 highlights the need for the development of active inclusion strategies that include broad access to affordable and high-quality health services, also with regard to achieving the objectives of Europe 2020;


The Council recalls that Council Recommendation 2009/C 151/01 and Directive 2011/247  request that patients receive healthcare in accordance with safety and quality standards and guidelines and clarify the right to receive information, in a clear and transparent way, as regards safety and quality measures in place and complaints procedures and redress mechanisms;


The Council recognises the main role of education and training on patient safety. Infection prevention and control should be embedded in training for health professionals and carers and be included in continuous professional development;


The Council notes that patient empowerment and involvement are recognised as an essential part of good quality and safety of care and require an effort by Member States to exchange crosscountry knowledge and effective tools;


The conclusions highlight the crucial work of the Patient Safety and Quality of Care Working Group on drafting practical guidelines on education and training and on reporting and learning systems and the council conclusions emphasise the need for continued and sustainable collaboration at EU level on patient safety and quality of care; and invite MS and EC to finalise by December 2016 a framework for a sustainable EU collaboration on patient safety and quality of care, also taking into account the results of the "Joint Action on patient safety and quality of care" (PaSQ);


Member State and EC should work towards a better understanding of the cost-effectiveness of patient safety policies under the principles of efficacy, efficiency, appropriateness, safety and quality of care; and strengthen and coordinate research and innovation efforts to address antimicrobial resistance, in particular by providing support to the Joint Programming Initiative on Antimicrobial Resistance.


Member States should:


·Promote the education and training of healthcare staff on patient safety and healthcare associated infections.

·Encourage the participation and empowerment of patients, families and their informal caregivers, as well as patient organisations, through evidence-based and unbiased provision of information and education, and promote patients' participation in decision-making in the healthcare process in order to contribute to the prevention of adverse events

Member States and the EU should:


·The European Commission should continue supporting Member States in improving strategies and programmes for patient safety in all settings of care and monitoring MS improvements on Patient safety.

·Develop EU guidance for patient/citizens' involvement in strategies on patient safety,

·taking into account the work of the World Health Organisation; The EU commission is invited to explore the feasibility to present a proposal for Council Recommendation on the provision of information to patients on patient safety.


Council conclusions on innovation for the benefit of patients


The Conclusions highlight the main role of the HTA as a health policy tool to support evidence-based, sustainable and equitable choices in healthcare and health technologies for the benefit of patients and underline the importance of the strategy adopted by the HTA Network on 29 October 2014.


The Council takes note that that in order to stimulate development, there is a need to facilitate the translation of scientific advances into innovative medicinal products that meet regulatory standards, accelerate patients’ access to innovative therapies with added value for patients and are affordable to the EU Member States' health systems;


Member State and EC should:

  • Explore opportunities for cooperation on exchange of information between competent bodies in relation to a ‘life cycle approach’ for innovative medicinal products, including, wherebappropriate:
  • Early dialogue and scientific advice; (b) Pricing and reimbursement models; (c) Registries for monitoring the effectiveness of therapies and technologies; (d) Appropriate re-assessments; (e) Post-authorisation studies;
  • ·Further enhance joint work on HTA and exchange views on how to make effective use of the existing EU regulatory tools of accelerated assessment, conditional marketing authorisation and authorisation in exceptional circumstances and on the effectiveness and impact of these tools while ensuring the high level of patient safety
  • ·Continue the dialogue between stakeholders and competent authorities, including pricing and reimbursement authorities, and examine opportunities for potential cooperation on a voluntary basis in the field of pricing and reimbursement and facilitate the launching of pilot projects in that field
  • Support the cooperation between Member States to implement the HTA strategy through a Joint Action under the third Programme for the Union's action in the field of health (2014-2020), while exploring options for continued and sustainable financing;
  • Continue to support research and information tools that aim to provide a better understanding of how pharmaceutical pricing may be applied to maximise benefits for patients and Member States’ health systems and, where relevant, to minimise possible unintended negative effects on patient access and health budgets."


More info:

Patient safety and quality of care, including the prevention and control of healthcare associated infections and antimicrobial


Innovation for the benefit of patients 



Symptom Tracker


This is a useful new tool - currently in test phase - to support patients with Ulcerative Colitis. If you would like to test the tool, you will need to introduce the following information:


username: This email address is being protected from spambots. You need JavaScript enabled to view it.

password: guest


Please check out the tool at:


Any feedback please send  to Isabella Haaf: This email address is being protected from spambots. You need JavaScript enabled to view it.


The tool is supported by an unrestricted grant from the pharmceutical company Shire. 

EFCCA Annual General Meeting 2014

Commissioner Borgh addressing EFCCA General Assembly


Commissioner Borgh from the European Commission´s Directorate for Health and Consumers welcomed delegates to the  24 General Assembly of EFCCA which took place in Graz (Austria) from 3-6 April 2014.


In his pre-recorded speech Commissioner Borgh acknowledged and applauded the work of EFCCA and showed his support to the efforts that the national associations and EFCCA were undertaking to improve the lives of people with IBD.


The link below is a small video illustrating the work that was being done in those two days.


All documents related to the GA are available to our members in the Members Only Section of our website. 




IBD11 - unleash your knowledge


EFCCA has been invited to speak at the IBD 11 meeting that took place in Prague (14-16 November). The meeting was organised by the pharmaceutical company Ferring and was attended by over 850 physicians from over 50 countries. Marco Greco, EFCCA chairman, presented during the opening session the work of EFCCA and the patient perspective. He put forward strong arguments for close cooperation between patients and doctors in order to ensure a better quality of life for people living with IBD. The meeting was an excellent opportunity for EFCCA to exchange information, to learn about the latest developments in IBD and to make new contacts and refresh exisiting links.


Download presentation


For more information please contact the EFCCA office. 


  • Clinical Trials


    EFCCA Clinical Trial News

    EFCCA is pleased to bring you some scientific and medical articles related to IBD for your information. EFCCA cannot accept any liability for the accuracy of the information, or for the use of it. Whilst discussion of potential therapies has academic value, EFCCA would like to remind all readers that no claims are made on the effectiveness or safety of any treatment, and that readers should always consult their healthcare professional if they have any concerns or questions, and before taking any action based on the information.